Trade Standard BioTools Inc - LAB CFD
Add to favourite- Summary
- Historical Data
Spread | 0.0200 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024124% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001901% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 1.625 |
Open | 1.595 |
1-Year Change | -30.46% |
Day's Range | 1.575 - 1.655 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Nov 22, 2024 | 1.5850 | -0.0500 | -3.06% | 1.6350 | 1.6550 | 1.5650 |
Nov 21, 2024 | 1.6250 | 0.0600 | 3.83% | 1.5650 | 1.6550 | 1.5550 |
Nov 20, 2024 | 1.6050 | 0.1100 | 7.36% | 1.4950 | 1.6750 | 1.4650 |
Nov 19, 2024 | 1.5050 | 0.0300 | 2.03% | 1.4750 | 1.5450 | 1.4550 |
Nov 18, 2024 | 1.4850 | -0.0700 | -4.50% | 1.5550 | 1.5650 | 1.4750 |
Nov 15, 2024 | 1.5750 | -0.1000 | -5.97% | 1.6750 | 1.7050 | 1.5650 |
Nov 14, 2024 | 1.6850 | -0.1100 | -6.13% | 1.7950 | 1.8150 | 1.6650 |
Nov 13, 2024 | 1.8350 | -0.1800 | -8.93% | 2.0150 | 2.0850 | 1.8350 |
Nov 12, 2024 | 2.0450 | -0.1600 | -7.26% | 2.2050 | 2.2150 | 2.0250 |
Nov 11, 2024 | 2.2250 | 0.0500 | 2.30% | 2.1750 | 2.2450 | 2.1250 |
Nov 8, 2024 | 2.1450 | -0.0300 | -1.38% | 2.1750 | 2.1950 | 2.1150 |
Nov 7, 2024 | 2.1750 | -0.0300 | -1.36% | 2.2050 | 2.3050 | 2.1550 |
Nov 6, 2024 | 2.2450 | 0.0400 | 1.81% | 2.2050 | 2.2550 | 2.0950 |
Nov 5, 2024 | 2.0950 | 0.0100 | 0.48% | 2.0850 | 2.2150 | 2.0450 |
Nov 4, 2024 | 2.0850 | 0.1000 | 5.04% | 1.9850 | 2.0950 | 1.9750 |
Nov 1, 2024 | 1.9850 | 0.0300 | 1.53% | 1.9550 | 2.1050 | 1.9550 |
Oct 31, 2024 | 1.9450 | 0.0000 | 0.00% | 1.9450 | 2.2450 | 1.9250 |
Oct 30, 2024 | 1.8650 | 0.1400 | 8.12% | 1.7250 | 1.9050 | 1.7150 |
Oct 29, 2024 | 1.7450 | 0.0300 | 1.75% | 1.7150 | 1.8050 | 1.6850 |
Oct 28, 2024 | 1.6850 | 0.0200 | 1.20% | 1.6650 | 1.7450 | 1.6650 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Standard BioTools Inc Company profile
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures, and markets a range of products and services, including instruments, consumables, reagents, and software that are used by researchers and clinical labs. The Company operates in development, manufacturing, and commercialization of tools for life sciences research. Its technology, mass cytometry is a multiplexed solution to analyze cell-surface and intracellular proteins simultaneously in cell suspensions including blood and disassociated tissues. Its Imaging Mass Cytometry (IMC) technology allows multiplexed imaging to understand the composition of tissue microenvironments at a subcellular 1-micron resolution. It markets technologies and life science tools, including preparatory and analytical instruments for mass cytometry, library prep, single cell genomics, and consumables, including integrated fluidic circuits (ifcs), assays, and reagents. Its analytical instruments include Biomark HD System, EP1 System, and Hyperion Tissue Imager.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Fluidigm Corporation revenues decreased 5% to $130.6M. Net loss increased 12% to $59.2M. Revenues reflect Development revenue segment decrease of 71% to $2.6M, Instruments segment decrease of 7% to $42.5M, United States segment decrease of 16% to $60.2M, Asia-Pacific segment decrease of 7% to $24M. Higher net loss reflects Research and development increase of 4% to $37.9M (expense), Selling.
Equity composition
Common Stock $0.001 Par, 2/11, 19,938,754 auth, 19,938,754 issd. Insiders own approx. 11.14%.
Industry: | Advanced Medical Equipment & Technology (NEC) |
2 Tower Place
Suite 2000
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
15:17, 18 November 2024Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com